Opinion|Videos|January 7, 2025
Current Treatment Options for BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
A panelist discusses how intravesical chemotherapy offers localized treatment with minimal systemic effects but requires frequent administration, while PD-L1 inhibitors show promising response rates yet come with immune-related adverse events, highlighting how each current treatment option presents distinct trade-offs among efficacy, safety, and convenience.
Advertisement
Episodes in this series
- Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.
- What advantages and limitations do these options have?
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
Patient Selection and Partnership in Prostate Radiotherapy Spacing
3
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
4
Alternative BCG strains may help address ongoing supply challenges in NMIBC
5